NEW YORK (GenomeWeb) – Cytox said today that it has raised £2.6 million ($3.3 million) in new financing. The British genetics company will use the proceeds to support the roll out of its Alzheimer's disease testing service.

GM&C Life Sciences Fund — a Manchester, UK-based seed and early stage venture capital fund managed by Catapult Ventures — led the round as a new investor. Existing investors Perivoli Innovations, the Rainbow Seed Fund, the University of Oxford, and other private investors also contributed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.